Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.21.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2017
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2018
Loss Contingencies [Line Items]        
Drug development costs to service   $ 166,929 $ 388,336  
License Agreement [Member] | QSAM Therapeutics Inc [Member]        
Loss Contingencies [Line Items]        
Payments for milestone $ 60,000      
Other Expenses     60,000  
Equity Method Investment, Ownership Percentage 5.00%      
Royalty percentage 4.50%      
Consulting fee     8,500  
Payment for license fees     $ 60,000  
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Upon Commercialization [Member]        
Loss Contingencies [Line Items]        
Other Expenses $ 1,500,000      
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member]        
Loss Contingencies [Line Items]        
Other Expenses $ 150,000      
Royalty percentage 50.00%      
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Minimum [Member]        
Loss Contingencies [Line Items]        
Royalty percentage 10.00%      
Services Agreement [Member]        
Loss Contingencies [Line Items]        
Class of Warrant or Right, Outstanding       6,000
Warrant term outstanding       five-year term
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 1.00